PSU Profiles
Keywords
Last Name
Institution

Allan Lipton

TitleProfessor
InstitutionCollege of Medicine
DepartmentMedicine
Address500 University Drive Hershey PA 17033
Mailbox: H046
Phone7175318677

 Overview 
 overview
PREFERRED TITLE/ROLE:

Physician, Professor of Medicine

EDUCATION:

Fellowship, Medical Oncology/Hematology, Memorial Sloan Kettering Cancer Center (1969)
Residency, Internal Medicine, Bellevue Hospital Center (New York University) (1965)
M.D., New York University, School of Medicine (1963)


 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Lipton A, Goodman L, Leitzel K, Cook J, Sperinde J, Haddad M, Köstler WJ, Huang W, Weidler JM, Ali S, Newton A, Fuchs EM, Paquet A, Singer CF, Horvat R, Jin X, Banerjee J, Mukherjee A, Tan Y, Shi Y, Chenna A, Larson J, Lie Y, Sherwood T, Petropoulos CJ, Williams S, Winslow J, Parry G, Bates M. HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2013 Aug; 141(1):43-53.
    View in: PubMed
  2. Casimiro S, Mohammad KS, Pires R, Tato-Costa J, Alho I, Teixeira R, Carvalho A, Ribeiro S, Lipton A, Guise TA, Costa L. RANKL/RANK/MMP-1 molecular triad contributes to the metastatic phenotype of breast and prostate cancer cells in vitro. PLoS One. 2013; 8(5):e63153.
    View in: PubMed
  3. Washam CL, Byrum SD, Leitzel K, Ali SM, Tackett AJ, Gaddy D, Sundermann SE, Lipton A, Suva LJ. Identification of PTHrP(12-48) as a plasma biomarker associated with breast cancer bone metastasis. Cancer Epidemiol Biomarkers Prev. 2013 May; 22(5):972-83.
    View in: PubMed
  4. Alkhateeb AA, Leitzel K, Ali SM, Campbell-Baird C, Evans M, Fuchs EM, Köstler WJ, Lipton A, Connor J. Elevation in inflammatory serum biomarkers predicts response to trastuzumab-containing therapy. PLoS One. 2012; 7(12):e51379.
    View in: PubMed
  5. Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, Richardson GE, Siena S, Maroto P, Clemens M, Bilynskyy B, Charu V, Beuzeboc P, Rader M, Viniegra M, Saad F, Ke C, Braun A, Jun S. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer. 2012 Nov; 48(16):3082-92.
    View in: PubMed
  6. Cleeland CS, Body JJ, Stopeck A, von Moos R, Fallowfield L, Mathias SD, Patrick DL, Clemons M, Tonkin K, Masuda N, Lipton A, de Boer R, Salvagni S, Oliveira CT, Qian Y, Jiang Q, Dansey R, Braun A, Chung K. Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid. Cancer. 2013 Feb 15; 119(4):832-8.
    View in: PubMed
  7. Brown JE, Cook RJ, Lipton A, Coleman RE. Serum lactate dehydrogenase is prognostic for survival in patients with bone metastases from breast cancer: a retrospective analysis in bisphosphonate-treated patients. Clin Cancer Res. 2012 Nov 15; 18(22):6348-55.
    View in: PubMed
  8. Lipton A, Smith MR, Ellis GK, Goessl C. Treatment-induced bone loss and fractures in cancer patients undergoing hormone ablation therapy: efficacy and safety of denosumab. Clin Med Insights Oncol. 2012; 6:287-303.
    View in: PubMed
  9. Lipton A, Balakumaran A. Denosumab for the treatment of cancer therapy-induced bone loss and prevention of skeletal-related events in patients with solid tumors. Expert Rev Clin Pharmacol. 2012 Jul; 5(4):359-71.
    View in: PubMed
  10. Costa L, Lipton A, Hadji P, Chen YM, Kosmidis P. Treatment of bone metastases before the onset of pain. Int J Clin Oncol. 2013 Jun; 18(3):531-8.
    View in: PubMed
  11. Berruti A, Cook R, Saad F, Buttigliero C, Lipton A, Tampellini M, Lee KA, Coleman RE, Smith MR. Prognostic role of serum parathyroid hormone levels in advanced prostate cancer patients undergoing zoledronic acid administration. Oncologist. 2012; 17(5):645-52.
    View in: PubMed
  12. Ha NH, Nair VS, Reddy DN, Mudvari P, Ohshiro K, Ghanta KS, Pakala SB, Li DQ, Costa L, Lipton A, Badwe RA, Fuqua S, Wallon M, Prendergast GC, Kumar R. Lactoferrin-endothelin-1 axis contributes to the development and invasiveness of triple-negative breast cancer phenotypes. Cancer Res. 2011 Dec 1; 71(23):7259-69.
    View in: PubMed
  13. Lipton A, Jacobs I. Denosumab: benefits of RANK ligand inhibition in cancer patients. Curr Opin Support Palliat Care. 2011 Sep; 5(3):258-64.
    View in: PubMed
  14. Lipton A, Chapman JA, Demers L, Shepherd LE, Han L, Wilson CF, Pritchard KI, Leitzel KE, Ali SM, Pollak M. Elevated bone turnover predicts for bone metastasis in postmenopausal breast cancer: results of NCIC CTG MA.14. J Clin Oncol. 2011 Sep 20; 29(27):3605-10.
    View in: PubMed
  15. Gralow JR, Lipton A, Stopeck AT. How do we define efficacy in comparing osteoclast-targeted agents in metastatic breast cancer? J Clin Oncol. 2011 Sep 10; 29(26):3591-2; author reply 3592-3.
    View in: PubMed
  16. Lipton A. Zoledronic acid: multiplicity of use across the cancer continuum. Expert Rev Anticancer Ther. 2011 Jul; 11(7):999-1012.
    View in: PubMed
  17. Gervais R, Hainsworth JD, Blais N, Besse B, Laskin J, Hamm JT, Lipton A, Albain KS, Masters GA, Natale RB, Selaru P, Kim ST, Chao RC, Page RD. Phase II study of sunitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer. Lung Cancer. 2011 Dec; 74(3):474-80.
    View in: PubMed
  18. Hatoum HT, Lin SJ, Smith MR, Guo A, Lipton A. Treatment persistence with monthly zoledronic acid is associated with lower risk and frequency of skeletal complications in patients with breast cancer and bone metastasis. Clin Breast Cancer. 2011 Jun; 11(3):177-83.
    View in: PubMed
  19. Sivendran S, Harvey H, Lipton A, Drabick J. Treatment of Langerhans cell histiocytosis bone lesions with zoledronic acid: a case series. Int J Hematol. 2011 Jun; 93(6):782-6.
    View in: PubMed
  20. Lipton A, Leitzel K, Ali SM, Carney W, Platek G, Steplewski K, Westlund R, Gagnon R, Martin AM, Maltzman J. Human epidermal growth factor receptor 2 (HER2) extracellular domain levels are associated with progression-free survival in patients with HER2-positive metastatic breast cancer receiving lapatinib monotherapy. Cancer. 2011 Nov 1; 117(21):5013-20.
    View in: PubMed
  21. Ghosh R, Narasanna A, Wang SE, Liu S, Chakrabarty A, Balko JM, González-Angulo AM, Mills GB, Penuel E, Winslow J, Sperinde J, Dua R, Pidaparthi S, Mukherjee A, Leitzel K, Kostler WJ, Lipton A, Bates M, Arteaga CL. Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers. Cancer Res. 2011 Mar 1; 71(5):1871-82.
    View in: PubMed
  22. Costa L, Harper P, Coleman RE, Lipton A. Anticancer evidence for zoledronic acid across the cancer continuum. Crit Rev Oncol Hematol. 2011 Feb; 77 Suppl 1:S31-7.
    View in: PubMed
  23. Lipton A. Denosumab in breast cancer. Curr Oncol Rep. 2011 Feb; 13(1):1-4.
    View in: PubMed
  24. Lipton A. Improving progression-free and overall survival in patients with cancer: a potential role for bisphosphonates. Expert Opin Pharmacother. 2011 Apr; 12(5):749-62.
    View in: PubMed
  25. Lipton A. New strategies to prevent and manage bone complications in cancer. Clin Adv Hematol Oncol. 2011 Jan; 9(1):42-4.
    View in: PubMed
  26. Coleman R, Cook R, Hirsh V, Major P, Lipton A. Zoledronic acid use in cancer patients: more than just supportive care? Cancer. 2011 Jan 1; 117(1):11-23.
    View in: PubMed
  27. Lipton A, Costa L, Coleman RE. Bone turnover markers: tools for prognosis and monitoring response to bisphosphonates? Breast Dis. 2011; 33(2):59-69.
    View in: PubMed
  28. Albain KS, Carey L, Gradishar WJ, Gralow JR, Lipton A, Rugo H, Tripathy D, Peck S, Abair T, Pegram M. Proceedings of the First Global Workshop on Breast Cancer: pathways to the evaluation and clinical development of novel agents for breast cancer. Clin Breast Cancer. 2010 Dec 1; 10(6):421-39.
    View in: PubMed
  29. Hatoum HT, Lin SJ, Guo A, Lipton A, Smith MR. Zoledronic acid therapy impacts risk and frequency of skeletal complications and follow-up duration in prostate cancer patients with bone metastasis. Curr Med Res Opin. 2011 Jan; 27(1):55-62.
    View in: PubMed
  30. Lipton A, Köstler WJ, Leitzel K, Ali SM, Sperinde J, Weidler J, Paquet A, Sherwood T, Huang W, Bates M. Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab. Cancer. 2010 Nov 15; 116(22):5168-78.
    View in: PubMed
  31. Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010 Dec 10; 28(35):5132-9.
    View in: PubMed
  32. Green J, Lipton A. Anticancer properties of zoledronic acid. Cancer Invest. 2010 Nov; 28(9):944-57.
    View in: PubMed
  33. Lipton A, Goessl C. Clinical development of anti-RANKL therapies for treatment and prevention of bone metastasis. Bone. 2011 Jan; 48(1):96-9.
    View in: PubMed
  34. Lipton A. Implications of bone metastases and the benefits of bone-targeted therapy. Semin Oncol. 2010 Oct; 37 Suppl 2:S15-29.
    View in: PubMed
  35. Morgan G, Lipton A. Antitumor effects and anticancer applications of bisphosphonates. Semin Oncol. 2010 Oct; 37 Suppl 2:S30-40.
    View in: PubMed
  36. Oh WK, Vargas R, Jacobus S, Leitzel K, Regan MM, Hamer P, Pierce K, Brown-Shimer S, Carney W, Ali SM, Kantoff PW, Lipton A. Elevated plasma tissue inhibitor of metalloproteinase-1 levels predict decreased survival in castration-resistant prostate cancer patients. Cancer. 2011 Feb 1; 117(3):517-25.
    View in: PubMed
  37. Hadji P, Gnant M, Aapro M, Lipton A, Coleman R. Dosing of zoledronic acid throughout the treatment continuum in breast cancer. Crit Rev Oncol Hematol. 2011 Aug; 79(2):175-88.
    View in: PubMed
  38. Lipton A. New approaches to treating and preventing bone metastases. Curr Opin Support Palliat Care. 2010 Sep; 4(3):178-81.
    View in: PubMed
  39. Saad F, Lipton A. Bone-marker levels in patients with prostate cancer: potential correlations with outcomes. Curr Opin Support Palliat Care. 2010 Sep; 4(3):127-34.
    View in: PubMed
  40. Sperinde J, Jin X, Banerjee J, Penuel E, Saha A, Diedrich G, Huang W, Leitzel K, Weidler J, Ali SM, Fuchs EM, Singer CF, Köstler WJ, Bates M, Parry G, Winslow J, Lipton A. Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients. Clin Cancer Res. 2010 Aug 15; 16(16):4226-35.
    View in: PubMed
  41. Brown JE, Cook RJ, Lipton A, Costa L, Coleman RE. Prognostic factors for skeletal complications from metastatic bone disease in breast cancer. Breast Cancer Res Treat. 2010 Oct; 123(3):767-79.
    View in: PubMed
  42. Lipton A. Bone loss prevention in cancer: new developments and perspectives. Semin Oncol. 2010 Jun; 37 Suppl 1:S1-2.
    View in: PubMed
  43. Lipton A. Bone continuum of cancer. Am J Clin Oncol. 2010 Jun; 33(3 Suppl):S1-7.
    View in: PubMed
  44. Lipton A. Should bisphosphonates be utilized in the adjuvant setting for breast cancer? Breast Cancer Res Treat. 2010 Aug; 122(3):627-36.
    View in: PubMed
  45. Coleman RE, Lipton A, Roodman GD, Guise TA, Boyce BF, Brufsky AM, Clézardin P, Croucher PI, Gralow JR, Hadji P, Holen I, Mundy GR, Smith MR, Suva LJ. Metastasis and bone loss: advancing treatment and prevention. Cancer Treat Rev. 2010 Dec; 36(8):615-20.
    View in: PubMed
  46. Lipton A, Campbell-Baird C, Witters L, Harvey H, Ali S. Phase II trial of gemcitabine, irinotecan, and celecoxib in patients with advanced pancreatic cancer. J Clin Gastroenterol. 2010 Apr; 44(4):286-8.
    View in: PubMed
  47. Body JJ, Lipton A, Gralow J, Steger GG, Gao G, Yeh H, Fizazi K. Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure. J Bone Miner Res. 2010 Mar; 25(3):440-6.
    View in: PubMed
  48. Lipton A, Campbell-Baird C, Harvey H, Kim C, Demers L, Costa L. Phase I trial of zoledronic acid + imatinib mesylate (Gleevec) in patients with bone metastases. Am J Clin Oncol. 2010 Feb; 33(1):75-8.
    View in: PubMed
  49. Saad F, Lipton A. SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer. Cancer Treat Rev. 2010 Apr; 36(2):177-84.
    View in: PubMed
  50. Ali SM, Leitzel K, Lipton A, Carney WP, Köstler WJ. Value of serum human epidermal growth factor receptor 2 (HER2)/neu testing for early prediction of response to HER2/neu-directed therapies is still an open one and deserves further study in large prospective trials. J Clin Oncol. 2009 Dec 20; 27(36):e273; author reply e274-5.
    View in: PubMed
  51. Karp DD, Pollak MN, Cohen RB, Eisenberg PD, Haluska P, Yin D, Lipton A, Demers L, Leitzel K, Hixon ML, Terstappen LW, Garland L, Paz-Ares LG, Cardenal F, Langer CJ, Gualberto A. Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatin. J Thorac Oncol. 2009 Nov; 4(11):1397-403.
    View in: PubMed
  52. Lipton A, Uzzo R, Amato RJ, Ellis GK, Hakimian B, Roodman GD, Smith MR. The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors. J Natl Compr Canc Netw. 2009 Oct; 7 Suppl 7:S1-29; quiz S30.
    View in: PubMed
  53. Terpos E, Dimopoulos MA, Shrivastava V, Leitzel K, Christoulas D, Migkou M, Gavriatopoulou M, Anargyrou K, Hamer P, Kastritis E, Carney W, Lipton A. High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents. Leuk Res. 2010 Mar; 34(3):399-402.
    View in: PubMed
  54. Major PP, Cook RJ, Lipton A, Smith MR, Terpos E, Coleman RE. Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity. BMC Cancer. 2009; 9:272.
    View in: PubMed
  55. Lipton A, Brown GA, Mundy GR, Roodman GD, Smith MR. New opportunities for the management of cancer-related bone complications. Clin Adv Hematol Oncol. 2009 May; 7(5 Suppl 11):1-30; quiz 31.
    View in: PubMed
  56. Fizazi K, Lipton A, Mariette X, Body JJ, Rahim Y, Gralow JR, Gao G, Wu L, Sohn W, Jun S. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol. 2009 Apr 1; 27(10):1564-71.
    View in: PubMed
  57. Coleman RE, Guise TA, Lipton A, Roodman GD, Berenson JR, Body JJ, Boyce BF, Calvi LM, Hadji P, McCloskey EV, Saad F, Smith MR, Suva LJ, Taichman RS, Vessella RL, Weilbaecher KN. Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference. Clin Cancer Res. 2008 Oct 15; 14(20):6387-95.
    View in: PubMed
  58. Lipton A, Steger GG, Figueroa J, Alvarado C, Solal-Celigny P, Body JJ, de Boer R, Berardi R, Gascon P, Tonkin KS, Coleman RE, Paterson AH, Gao GM, Kinsey AC, Peterson MC, Jun S. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clin Cancer Res. 2008 Oct 15; 14(20):6690-6.
    View in: PubMed
  59. Hatoum HT, Lin SJ, Smith MR, Barghout V, Lipton A. Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims database. Cancer. 2008 Sep 15; 113(6):1438-45.
    View in: PubMed
  60. Ali SM, Carney WP, Esteva FJ, Fornier M, Harris L, Köstler WJ, Lotz JP, Luftner D, Pichon MF, Lipton A. Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer. Cancer. 2008 Sep 15; 113(6):1294-301.
    View in: PubMed
  61. Lipton A, Jun S. RANKL inhibition in the treatment of bone metastases. Curr Opin Support Palliat Care. 2008 Sep; 2(3):197-203.
    View in: PubMed
  62. Witters L, Scherle P, Friedman S, Fridman J, Caulder E, Newton R, Lipton A. Synergistic inhibition with a dual epidermal growth factor receptor/HER-2/neu tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitor. Cancer Res. 2008 Sep 1; 68(17):7083-9.
    View in: PubMed
  63. Lipton A, Cook R, Saad F, Major P, Garnero P, Terpos E, Brown JE, Coleman RE. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer. 2008 Jul 1; 113(1):193-201.
    View in: PubMed
  64. Coleman R, Brown J, Terpos E, Lipton A, Smith MR, Cook R, Major P. Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions. Cancer Treat Rev. 2008 Nov; 34(7):629-39.
    View in: PubMed
  65. Lipton A. Emerging role of bisphosphonates in the clinic--antitumor activity and prevention of metastasis to bone. Cancer Treat Rev. 2008; 34 Suppl 1:S25-30.
    View in: PubMed
  66. Coleman RE, Body JJ, Gralow JR, Lipton A. Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies. Cancer Treat Rev. 2008; 34 Suppl 1:S31-42.
    View in: PubMed
  67. Lipton A, Leitzel K, Chaudri-Ross HA, Evans DB, Ali SM, Demers L, Hamer P, Brown-Shimer S, Pierce K, Gaur V, Carney W. Serum TIMP-1 and response to the aromatase inhibitor letrozole versus tamoxifen in metastatic breast cancer. J Clin Oncol. 2008 Jun 1; 26(16):2653-8.
    View in: PubMed
  68. Costa L, Badia X, Chow E, Lipton A, Wardley A. Impact of skeletal complications on patients' quality of life, mobility, and functional independence. Support Care Cancer. 2008 Aug; 16(8):879-89.
    View in: PubMed
  69. Hirsh V, Major PP, Lipton A, Cook RJ, Langer CJ, Smith MR, Brown JE, Coleman RE. Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J Thorac Oncol. 2008 Mar; 3(3):228-36.
    View in: PubMed
  70. Saad F, Lipton A. Clinical benefits and considerations of bisphosphonate treatment in metastatic bone disease. Semin Oncol. 2007 Dec; 34(6 Suppl 4):S17-23.
    View in: PubMed
  71. Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer. 2007 Oct 15; 110(8):1860-7.
    View in: PubMed
  72. Lipton A, Steger GG, Figueroa J, Alvarado C, Solal-Celigny P, Body JJ, de Boer R, Berardi R, Gascon P, Tonkin KS, Coleman R, Paterson AH, Peterson MC, Fan M, Kinsey A, Jun S. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol. 2007 Oct 1; 25(28):4431-7.
    View in: PubMed
  73. Lipton A, Cook RJ, Major P, Smith MR, Coleman RE. Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. Oncologist. 2007 Sep; 12(9):1035-43.
    View in: PubMed
  74. Smith MR, Cook RJ, Coleman R, Brown J, Lipton A, Major P, Hei YJ, Saad F. Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer. Urology. 2007 Aug; 70(2):315-9.
    View in: PubMed
  75. Lipton A. Efficacy and safety of intravenous bisphosphonates in patients with bone metastases caused by metastatic breast cancer. Clin Breast Cancer. 2007 Jul; 7 Suppl 1:S14-20.
    View in: PubMed
  76. Lipton A, Gnant M, Aapro M. Managing aromatase inhibitor-associated bone loss in breast cancer. Womens Health (Lond Engl). 2007 Jul; 3(4):441-8.
    View in: PubMed
  77. Fury MG, Lipton A, Smith KM, Winston CB, Pfister DG. A phase-I trial of the epidermal growth factor receptor directed bispecific antibody MDX-447 without and with recombinant human granulocyte-colony stimulating factor in patients with advanced solid tumors. Cancer Immunol Immunother. 2008 Feb; 57(2):155-63.
    View in: PubMed
  78. Lipton A, Ali SM, Leitzel K, Demers L, Evans DB, Hamer P, Brown-Shimer S, Pierce K, Carney W. Elevated plasma tissue inhibitor of metalloproteinase-1 level predicts decreased response and survival in metastatic breast cancer. Cancer. 2007 May 15; 109(10):1933-9.
    View in: PubMed
  79. Lipton A. The safety of zoledronic acid. Expert Opin Drug Saf. 2007 May; 6(3):305-13.
    View in: PubMed
  80. Lipton A, Cook RJ, Coleman RE, Smith MR, Major P, Terpos E, Berenson JR. Clinical utility of biochemical markers of bone metabolism for improving the management of patients with advanced multiple myeloma. Clin Lymphoma Myeloma. 2007 Mar; 7(5):346-53.
    View in: PubMed
  81. Witters LM, Witkoski A, Planas-Silva MD, Berger M, Viallet J, Lipton A. Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor. Oncol Rep. 2007 Feb; 17(2):465-9.
    View in: PubMed
  82. Lipton A. Treatment of bone metastases and bone pain with bisphosphonates. Support Cancer Ther. 2007 Jan 1; 4(2):92-100.
    View in: PubMed
  83. Carney WP, Leitzel K, Ali S, Neumann R, Lipton A. HER-2/neu diagnostics in breast cancer. Breast Cancer Res. 2007; 9(3):207.
    View in: PubMed
  84. Souder C, Leitzel K, Ali SM, Demers L, Evans DB, Chaudri-Ross HA, Hackl W, Hamer P, Carney W, Lipton A. Serum epidermal growth factor receptor/HER-2 predicts poor survival in patients with metastatic breast cancer. Cancer. 2006 Nov 15; 107(10):2337-45.
    View in: PubMed
  85. Lipton A, Berenson JR, Body JJ, Boyce BF, Bruland OS, Carducci MA, Cleeland CS, Clohisy DR, Coleman RE, Cook RJ, Guise TA, Pearse RN, Powles TJ, Rogers MJ, Roodman GD, Smith MR, Suva LJ, Vessella RL, Weilbaecher KN, King L. Advances in treating metastatic bone cancer: summary statement for the First Cambridge Conference. Clin Cancer Res. 2006 Oct 15; 12(20 Pt 2):6209s-6212s.
    View in: PubMed
  86. Lipton A. Future treatment of bone metastases. Clin Cancer Res. 2006 Oct 15; 12(20 Pt 2):6305s-6308s.
    View in: PubMed
  87. Saad F, Lipton A. Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers. BJU Int. 2006 Jun; 97(6):1351-2.
    View in: PubMed
  88. Cook RJ, Coleman R, Brown J, Lipton A, Major P, Hei YJ, Saad F, Smith MR. Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clin Cancer Res. 2006 Jun 1; 12(11 Pt 1):3361-7.
    View in: PubMed
  89. Costa L, Lipton A, Coleman RE. Role of bisphosphonates for the management of skeletal complications and bone pain from skeletal metastases. Support Cancer Ther. 2006 Apr 1; 3(3):143-53.
    View in: PubMed
  90. Body JJ, Facon T, Coleman RE, Lipton A, Geurs F, Fan M, Holloway D, Peterson MC, Bekker PJ. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res. 2006 Feb 15; 12(4):1221-8.
    View in: PubMed
  91. Lipton A. Biochemical bone markers in breast cancer. Cancer Treat Rev. 2006; 32 Suppl 1:20-2.
    View in: PubMed
  92. Saad F, Lipton A. Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers. BJU Int. 2005 Nov; 96(7):964-9.
    View in: PubMed
  93. Rascovsky K, Salmon DP, Lipton AM, Leverenz JB, DeCarli C, Jagust WJ, Clark CM, Mendez MF, Tang-Wai DF, Graff-Radford NR, Galasko D. Rate of progression differs in frontotemporal dementia and Alzheimer disease. Neurology. 2005 Aug 9; 65(3):397-403.
    View in: PubMed
  94. Lipton A, Leitzel K, Ali SM, Demers L, Harvey HA, Chaudri-Ross HA, Evans D, Lang R, Hackl W, Hamer P, Carney W. Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy. Cancer. 2005 Jul 15; 104(2):257-63.
    View in: PubMed
  95. Coleman RE, Major P, Lipton A, Brown JE, Lee KA, Smith M, Saad F, Zheng M, Hei YJ, Seaman J, Cook R. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol. 2005 Aug 1; 23(22):4925-35.
    View in: PubMed
  96. Lipton A. New therapeutic agents for the treatment of bone diseases. Expert Opin Biol Ther. 2005 Jun; 5(6):817-32.
    View in: PubMed
  97. Lipton A. Management of bone metastases in breast cancer. Curr Treat Options Oncol. 2005 Mar; 6(2):161-71.
    View in: PubMed
  98. Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M, Lee KA, Zheng M, Hei YJ, Coleman RE. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst. 2005 Jan 5; 97(1):59-69.
    View in: PubMed
  99. Lipton A, Harvey H, Witters L, Kerr S, Legore K, Campbell C. Gemcitabine/Irinotecan/celecoxib in pancreatic cancer. Oncology (Williston Park). 2004 Dec; 18(14 Suppl 14):43-5.
    View in: PubMed
  100. Atkins MB, Avigan DE, Bukowski RM, Childs RW, Dutcher JP, Eisen TG, Figlin RA, Finke JH, Flanigan RC, George DJ, Goldberg SN, Gordon MS, Iliopoulos O, Kaelin WG, Linehan WM, Lipton A, Motzer RJ, Novick AC, Stadler WM, Teh BT, Yang JC, King L. Innovations and challenges in renal cancer: consensus statement from the first international conference. Clin Cancer Res. 2004 Sep 15; 10(18 Pt 2):6277S-81S.
    View in: PubMed
  101. Lipton A, Colombo-Berra A, Bukowski RM, Rosen L, Zheng M, Urbanowitz G. Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid. Clin Cancer Res. 2004 Sep 15; 10(18 Pt 2):6397S-403S.
    View in: PubMed
  102. Carney WP, Neumann R, Lipton A, Leitzel K, Ali S, Price CP. Monitoring the circulating levels of the HER2/neu oncoprotein in breast cancer. Clin Breast Cancer. 2004 Jun; 5(2):105-16.
    View in: PubMed
  103. Lipton A. Pathophysiology of bone metastases: how this knowledge may lead to therapeutic intervention. J Support Oncol. 2004 May-Jun; 2(3):205-13; discussion 213-4, 216-7, 219-20.
    View in: PubMed
  104. Lipton A, Leitzel K, Ali S. Predicting response to herceptin therapy. Clin Cancer Res. 2004 Mar 1; 10(5):1559-60.
    View in: PubMed
  105. Witters LM, Myers A, Lipton A. Combining flavopiridol with various signal transduction inhibitors. Oncol Rep. 2004 Mar; 11(3):693-8.
    View in: PubMed
  106. Lipton A. Toward new horizons: the future of bisphosphonate therapy. Oncologist. 2004; 9 Suppl 4:38-47.
    View in: PubMed
  107. Lipton A. Bisphosphonate therapy in the oncology setting. Expert Opin Emerg Drugs. 2003 Nov; 8(2):469-88.
    View in: PubMed
  108. Carney WP, Neumann R, Lipton A, Leitzel K, Ali S, Price CP. Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer. Clin Chem. 2003 Oct; 49(10):1579-98.
    View in: PubMed
  109. Demers LM, Costa L, Lipton A. Biochemical markers and skeletal metastases. Clin Orthop Relat Res. 2003 Oct; (415 Suppl):S138-47.
    View in: PubMed
  110. Ali SM, Harvey HA, Lipton A. Metastatic breast cancer: overview of treatment. Clin Orthop Relat Res. 2003 Oct; (415 Suppl):S132-7.
    View in: PubMed
  111. Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, Cauley JA, Blumenstein BA, Albain KS, Lipton A, Brown S. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol. 2003 Nov 1; 21(21):4042-57.
    View in: PubMed
  112. Lipton A, Zheng M, Seaman J. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer. 2003 Sep 1; 98(5):962-9.
    View in: PubMed
  113. Witters LM, Crispino J, Fraterrigo T, Green J, Lipton A. Effect of the combination of docetaxel, zoledronic acid, and a COX-2 inhibitor on the growth of human breast cancer cell lines. Am J Clin Oncol. 2003 Aug; 26(4):S92-7.
    View in: PubMed
  114. Lipton A. Bone metastases in breast cancer. Curr Treat Options Oncol. 2003 Apr; 4(2):151-8.
    View in: PubMed
  115. Body JJ, Greipp P, Coleman RE, Facon T, Geurs F, Fermand JP, Harousseau JL, Lipton A, Mariette X, Williams CD, Nakanishi A, Holloway D, Martin SW, Dunstan CR, Bekker PJ. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer. 2003 Feb 1; 97(3 Suppl):887-92.
    View in: PubMed
  116. Witters LM, Santala SM, Engle L, Chinchilli V, Lipton A. Decreased response to paclitaxel versus docetaxel in HER-2/neu transfected human breast cancer cells. Am J Clin Oncol. 2003 Feb; 26(1):50-4.
    View in: PubMed
  117. Lipton A. Bisphosphonates and metastatic breast carcinoma. Cancer. 2003 Feb 1; 97(3 Suppl):848-53.
    View in: PubMed
  118. Clarke LE, Leitzel K, Smith J, Ali SM, Lipton A. Epidermal growth factor receptor mRNA in peripheral blood of patients with pancreatic, lung, and colon carcinomas detected by RT-PCR. Int J Oncol. 2003 Feb; 22(2):425-30.
    View in: PubMed
  119. Witters L, Engle L, Lipton A. Restoration of estrogen responsiveness by blocking the HER-2/neu pathway. Oncol Rep. 2002 Nov-Dec; 9(6):1163-6.
    View in: PubMed
  120. Berenson JR, Hillner BE, Kyle RA, Anderson K, Lipton A, Yee GC, Biermann JS. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2002 Sep 1; 20(17):3719-36.
    View in: PubMed
  121. Ali SM, Leitzel K, Chinchilli VM, Engle L, Demers L, Harvey HA, Carney W, Allard JW, Lipton A. Relationship of serum HER-2/neu and serum CA 15-3 in patients with metastatic breast cancer. Clin Chem. 2002 Aug; 48(8):1314-20.
    View in: PubMed
  122. Lipton A, Ali SM, Leitzel K, Chinchilli V, Witters L, Engle L, Holloway D, Bekker P, Dunstan CR. Serum osteoprotegerin levels in healthy controls and cancer patients. Clin Cancer Res. 2002 Jul; 8(7):2306-10.
    View in: PubMed
  123. Lipton A, Ali SM, Leitzel K, Demers L, Chinchilli V, Engle L, Harvey HA, Brady C, Nalin CM, Dugan M, Carney W, Allard J. Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol. 2002 Mar 15; 20(6):1467-72.
    View in: PubMed
  124. Costa L, Demers LM, Gouveia-Oliveira A, Schaller J, Costa EB, de Moura MC, Lipton A. Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. J Clin Oncol. 2002 Feb 1; 20(3):850-6.
    View in: PubMed
  125. Lipton A, Small E, Saad F, Gleason D, Gordon D, Smith M, Rosen L, Kowalski MO, Reitsma D, Seaman J. The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. Cancer Invest. 2002; 20 Suppl 2:45-54.
    View in: PubMed
Lipton's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
Co-Authors
_
Similar People
_
Same Department
Physical Neighbors
_